Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis

OBJECTIVES: The safety and efficacy of the 3C-like protease inhibitor GC376 was tested on a cohort of client-owned cats with various forms of feline infectious peritonitis (FIP). METHODS: Twenty cats from 3.3–82 months of age (mean 10.4 months) with various forms of FIP were accepted into a field tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Pedersen, Niels C, Kim, Yunjeong, Liu, Hongwei, Galasiti Kankanamalage, Anushka C, Eckstrand, Chrissy, Groutas, William C, Bannasch, Michael, Meadows, Juliana M, Chang, Kyeong-Ok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871025/
https://www.ncbi.nlm.nih.gov/pubmed/28901812
http://dx.doi.org/10.1177/1098612X17729626
_version_ 1783309587853606912
author Pedersen, Niels C
Kim, Yunjeong
Liu, Hongwei
Galasiti Kankanamalage, Anushka C
Eckstrand, Chrissy
Groutas, William C
Bannasch, Michael
Meadows, Juliana M
Chang, Kyeong-Ok
author_facet Pedersen, Niels C
Kim, Yunjeong
Liu, Hongwei
Galasiti Kankanamalage, Anushka C
Eckstrand, Chrissy
Groutas, William C
Bannasch, Michael
Meadows, Juliana M
Chang, Kyeong-Ok
author_sort Pedersen, Niels C
collection PubMed
description OBJECTIVES: The safety and efficacy of the 3C-like protease inhibitor GC376 was tested on a cohort of client-owned cats with various forms of feline infectious peritonitis (FIP). METHODS: Twenty cats from 3.3–82 months of age (mean 10.4 months) with various forms of FIP were accepted into a field trial. Fourteen cats presented with wet or dry-to-wet FIP and six cats presented with dry FIP. GC376 was administered subcutaneously every 12 h at a dose of 15 mg/kg. Cats with neurologic signs were excluded from the study. RESULTS: Nineteen of 20 cats treated with GC376 regained outward health within 2 weeks of initial treatment. However, disease signs recurred 1–7 weeks after primary treatment and relapses and new cases were ultimately treated for a minimum of 12 weeks. Relapses no longer responsive to treatment occurred in 13 of these 19 cats within 1–7 weeks of initial or repeat treatment(s). Severe neurologic disease occurred in 8/13 cats that failed treatment and five cats had recurrences of abdominal lesions. At the time of writing, seven cats were in disease remission. Five kittens aged 3.3–4.4 months with wet FIP were treated for 12 weeks and have been in disease remission after stopping treatment and at the time of writing for 5–14 months (mean 11.2 months). A sixth kitten was in remission for 10 weeks after 12 weeks of treatment, relapsed and is responding to a second round of GC376. The seventh was a 6.8-year-old cat with only mesenteric lymph node involvement that went into remission after three relapses that required progressively longer repeat treatments over a 10 month period. Side effects of treatment included transient stinging upon injection and occasional foci of subcutaneous fibrosis and hair loss. There was retarded development and abnormal eruption of permanent teeth in cats treated before 16–18 weeks of age. CONCLUSIONS AND RELEVANCE: GC376 showed promise in treating cats with certain presentations of FIP and has opened the door to targeted antiviral drug therapy.
format Online
Article
Text
id pubmed-5871025
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-58710252018-04-04 Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis Pedersen, Niels C Kim, Yunjeong Liu, Hongwei Galasiti Kankanamalage, Anushka C Eckstrand, Chrissy Groutas, William C Bannasch, Michael Meadows, Juliana M Chang, Kyeong-Ok J Feline Med Surg Original Articles OBJECTIVES: The safety and efficacy of the 3C-like protease inhibitor GC376 was tested on a cohort of client-owned cats with various forms of feline infectious peritonitis (FIP). METHODS: Twenty cats from 3.3–82 months of age (mean 10.4 months) with various forms of FIP were accepted into a field trial. Fourteen cats presented with wet or dry-to-wet FIP and six cats presented with dry FIP. GC376 was administered subcutaneously every 12 h at a dose of 15 mg/kg. Cats with neurologic signs were excluded from the study. RESULTS: Nineteen of 20 cats treated with GC376 regained outward health within 2 weeks of initial treatment. However, disease signs recurred 1–7 weeks after primary treatment and relapses and new cases were ultimately treated for a minimum of 12 weeks. Relapses no longer responsive to treatment occurred in 13 of these 19 cats within 1–7 weeks of initial or repeat treatment(s). Severe neurologic disease occurred in 8/13 cats that failed treatment and five cats had recurrences of abdominal lesions. At the time of writing, seven cats were in disease remission. Five kittens aged 3.3–4.4 months with wet FIP were treated for 12 weeks and have been in disease remission after stopping treatment and at the time of writing for 5–14 months (mean 11.2 months). A sixth kitten was in remission for 10 weeks after 12 weeks of treatment, relapsed and is responding to a second round of GC376. The seventh was a 6.8-year-old cat with only mesenteric lymph node involvement that went into remission after three relapses that required progressively longer repeat treatments over a 10 month period. Side effects of treatment included transient stinging upon injection and occasional foci of subcutaneous fibrosis and hair loss. There was retarded development and abnormal eruption of permanent teeth in cats treated before 16–18 weeks of age. CONCLUSIONS AND RELEVANCE: GC376 showed promise in treating cats with certain presentations of FIP and has opened the door to targeted antiviral drug therapy. SAGE Publications 2018-04 /pmc/articles/PMC5871025/ /pubmed/28901812 http://dx.doi.org/10.1177/1098612X17729626 Text en © The Author(s) 2017 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Articles
Pedersen, Niels C
Kim, Yunjeong
Liu, Hongwei
Galasiti Kankanamalage, Anushka C
Eckstrand, Chrissy
Groutas, William C
Bannasch, Michael
Meadows, Juliana M
Chang, Kyeong-Ok
Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis
title Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis
title_full Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis
title_fullStr Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis
title_full_unstemmed Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis
title_short Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis
title_sort efficacy of a 3c-like protease inhibitor in treating various forms of acquired feline infectious peritonitis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871025/
https://www.ncbi.nlm.nih.gov/pubmed/28901812
http://dx.doi.org/10.1177/1098612X17729626
work_keys_str_mv AT pedersennielsc efficacyofa3clikeproteaseinhibitorintreatingvariousformsofacquiredfelineinfectiousperitonitis
AT kimyunjeong efficacyofa3clikeproteaseinhibitorintreatingvariousformsofacquiredfelineinfectiousperitonitis
AT liuhongwei efficacyofa3clikeproteaseinhibitorintreatingvariousformsofacquiredfelineinfectiousperitonitis
AT galasitikankanamalageanushkac efficacyofa3clikeproteaseinhibitorintreatingvariousformsofacquiredfelineinfectiousperitonitis
AT eckstrandchrissy efficacyofa3clikeproteaseinhibitorintreatingvariousformsofacquiredfelineinfectiousperitonitis
AT groutaswilliamc efficacyofa3clikeproteaseinhibitorintreatingvariousformsofacquiredfelineinfectiousperitonitis
AT bannaschmichael efficacyofa3clikeproteaseinhibitorintreatingvariousformsofacquiredfelineinfectiousperitonitis
AT meadowsjulianam efficacyofa3clikeproteaseinhibitorintreatingvariousformsofacquiredfelineinfectiousperitonitis
AT changkyeongok efficacyofa3clikeproteaseinhibitorintreatingvariousformsofacquiredfelineinfectiousperitonitis